Given that hepatic glycogenolysis is more responsive to insulin and glucagon than gluconeogenesis in vivo (26, 27), it would stand to reason that an elevation in its rate would be a focal point in the pathology of T2D. The gene discussed is GCG; the disease is type 2 diabetes mellitus.